CRITERIA FOR THE IDENTIFICATION OF NONREDOX INHIBITORS OF 5-LIPOXYGENASE

被引:51
作者
FALGUEYRET, JP
HUTCHINSON, JH
RIENDEAU, D
机构
[1] MERCK FROST CTR THERAPEUT RES, DEPT BIOCHEM, KIRKLAND H9H 3L1, PQ, CANADA
[2] MERCK FROST CTR THERAPEUT RES, DEPT MED CHEM, KIRKLAND H9H 3L1, PQ, CANADA
关键词
D O I
10.1016/0006-2952(93)90185-Y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Methoxyalkyl thiazoles have been identified as a novel series of selective 5-lipoxygenase inhibitors with anti-inflammatory properties (Bird et al., J Med Chem 34: 2176-2186, 1991). Based on their structure, it was proposed that the potency of these compounds is not due to redox or iron-chelating properties. In the studies reported here, it was found that the model compounds 1-[3-(naphth-2-ylmethoxy) phenyl]-1-(thiazol-2-yl)propyl methyl ether (ICI 211965) and 3-[1-(4-chlorobenzyl)-4-methyl-(5-phenylpyridin-2-ylmethoxy)-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropanoic acid (L-689,065) (1) are inactive as reducing substrates in the 5-lipoxygenase-catalyzed decomposition of lipid hydroperoxides, (2) inhibit the 5-lipoxygenase-catalyzed reaction of reducing agents with lipid hydroperoxides, and (3) strongly inhibit the turnover-dependent inactivation of 5-lipoxygenase. These three observations with ICI 211965 and L-689,065 are in contrast to the behavior of other potent 5-lipoxygenase inhibitors from other structural classes, such as L-670,630, BW A4C, and zileuton, which all function as reducing substrates for 5-lipoxygenase. The data indicate that methoxyalkyl thiazoles and thiopyranoindoles are reversible dead-end inhibitors of 5-lipoxygenase and that the effects of inhibitors on the pseudoperoxidase activity and rate of enzyme inactivation provide simple tests to distinguish between redox and non-redox inhibitors of 5-lipoxygenase.
引用
收藏
页码:978 / 981
页数:4
相关论文
共 17 条
[1]   (METHOXYALKYL)THIAZOLES - A NEW SERIES OF POTENT, SELECTIVE, AND ORALLY ACTIVE 5-LIPOXYGENASE INHIBITORS DISPLAYING HIGH ENANTIOSELECTIVITY [J].
BIRD, TGC ;
BRUNEAU, P ;
CRAWLEY, GC ;
EDWARDS, MP ;
FOSTER, SJ ;
GIRODEAU, JM ;
KINGSTON, JF ;
MCMILLAN, RM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) :2176-2186
[2]  
CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929
[3]   INHIBITION OF SOYBEAN LIPOXYGENASE-1 BY N-ALKYLHYDROXYLAMINES [J].
CLAPP, CH ;
BANERJEE, A ;
ROTENBERG, SA .
BIOCHEMISTRY, 1985, 24 (08) :1826-1830
[4]  
DENIS D, 1991, J BIOL CHEM, V266, P5072
[5]  
DEWOLF WE, 1991, LIPOXYGENASES THEIR, P105
[6]   DEVELOPMENT OF L-689,065 - THE PROTOTYPE OF A NEW CLASS OF POTENT 5-LIPOXYGENASE INHIBITORS [J].
HUTCHINSON, JH ;
PRASIT, P ;
CHOO, LY ;
RIENDEAU, D ;
CHARLESON, S ;
EVANS, JF ;
PIECHUTA, H ;
BALL, RG .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1992, 2 (12) :1699-1702
[7]   ACETOHYDROXAMIC ACIDS AS POTENT, SELECTIVE, ORALLY ACTIVE 5-LIPOXYGENASE INHIBITORS [J].
JACKSON, WP ;
ISLIP, PJ ;
KNEEN, G ;
PUGH, A ;
WATES, PJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (03) :499-500
[8]   REDUCTIVE INACTIVATION OF SOYBEAN LIPOXYGENASE-1 BY CATECHOLS - A POSSIBLE MECHANISM FOR REGULATION OF LIPOXYGENASE ACTIVITY [J].
KEMAL, C ;
LOUISFLAMBERG, P ;
KRUPINSKIOLSEN, R ;
SHORTER, AL .
BIOCHEMISTRY, 1987, 26 (22) :7064-7072
[9]   BRONCHODILATOR PROPERTIES OF AN INHALED LEUKOTRIENE-D4 ANTAGONIST (VERLUKAST-MK-0679) IN ASTHMATIC-PATIENTS [J].
LAMMERS, JWJ ;
VANDAELE, P ;
VANDENELSHOUT, FMJ ;
DECRAMER, M ;
BUNTINX, A ;
DELEPELEIRE, I ;
FRIEDMAN, B .
PULMONARY PHARMACOLOGY, 1992, 5 (02) :121-125
[10]   DEVELOPMENT OF 2,3-DIHYDRO-6-(3-PHENOXYPROPYL)-2-(2-PHENYLETHYL)-5-BENZOFURANOL (L-670,630) AS A POTENT AND ORALLY ACTIVE INHIBITOR OF 5-LIPOXYGENASE [J].
LAU, CK ;
BELANGER, PC ;
DUFRESNE, C ;
SCHEIGETZ, J ;
THERIEN, M ;
FITZSIMMONS, B ;
YOUNG, RN ;
FORDHUTCHINSON, AW ;
RIENDEAU, D ;
DENIS, D ;
GUAY, J ;
CHARLESON, S ;
PIECHUTA, H ;
MCFARLANE, CS ;
CHIU, SHL ;
ELINE, D ;
ALVARO, RF ;
MIWA, G ;
WALSH, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (07) :1299-1318